Current Investments
CrossBridge Bio, Inc. - Next-generation Antibody Drug Conjugates
AstralBio, Inc. - Next-generation Antibodies for Cardiometabolic Diseases
Mach5 Therapeutics, Inc. - Innovative Biologics for Chronic Inflammatory Disorders
Prior Ventures
Pyros Pharmaceuticals, Inc. (acquired in 2024 by Bora Pharmaceuticals)
AlmataBio, Inc. (acquired in 2024 by Avalo Therapeutics)
ValenzaBio, Inc. (acquired in 2023 by Acelyrin)
Ichorion Therapeutics, Inc. (acquired in 2018 by Cerecor)